Showing results (191-200 of 237) with videos related to

Sort By:
Pageof 24
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2019
Intermediate-scale horizontal isoprene concentrations in the near-canopy forest atmosphere and implications for emission heterogeneityCarla E Batista, Jianhuai Ye, Igor O Ribeiro, et al.
BMJ (Clinical Research Ed.)|November 17, 2022
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trialMeg J Jardine, Sradha S Kotwal, Abhinav Bassi, et al.
Journal of the American College of Cardiology|October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and AlbuminuriaAshish Sarraju, George Bakris, Christopher P Cannon, et al.
Journal of Nematology|March 5, 2009
Assessing Heterodera glycines-Resistant and Susceptible Cultivar Yield ResponseP A Donald, P E Pierson, S K St Martin, et al.
Annals of Internal Medicine|July 16, 2019
Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysisJeffrey T Ha, Brendon L Neuen, Lap P Cheng, et al.
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
BMC Nephrology|April 19, 2018
Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patientsR Krishnasamy, C M Hawley, M J Jardine, et al.
Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.
Pageof 24